Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions.
BCL-2
biomarkers
chemoresistance
treatment response
venetoclax
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Jun 2021
14 Jun 2021
Historique:
received:
27
05
2021
revised:
03
06
2021
accepted:
04
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Intrinsic apoptotic pathway dysregulation plays an essential role in all cancers, particularly hematologic malignancies. This role has led to the development of multiple therapeutic agents targeting this pathway. Venetoclax is a selective BCL-2 inhibitor that has been approved for the treatment of chronic lymphoid leukemia and acute myeloid leukemia. Given the reported resistance to venetoclax, understanding the mechanisms of resistance and the potential biomarkers of response is crucial to ensure optimal drug usage and improved patient outcomes. Mechanisms of resistance to venetoclax include alterations involving the BH3-binding groove,
Identifiants
pubmed: 34198580
pii: cancers13122974
doi: 10.3390/cancers13122974
pmc: PMC8231978
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Nat Cancer. 2020 Aug;1(8):826-839
pubmed: 33123685
Leuk Lymphoma. 2017 Sep;58(9):1-17
pubmed: 28140720
Sci Rep. 2017 Dec 21;7(1):18007
pubmed: 29269870
Clin Cancer Res. 2017 Aug 15;23(16):4527-4533
pubmed: 28100580
Br J Haematol. 2013 Oct;163(1):139-42
pubmed: 23826785
Leuk Lymphoma. 2021 May;62(5):1129-1135
pubmed: 33327833
Cancer Res. 2015 Apr 1;75(7):1366-75
pubmed: 25649768
Cell Death Differ. 2018 Jan;25(1):27-36
pubmed: 29099483
Arch Pathol Lab Med. 2015 Jan;139(1):11-3
pubmed: 25166874
J Hematol Oncol. 2015 Nov 20;8:129
pubmed: 26589495
J Pathol. 2003 Jan;199(1):90-7
pubmed: 12474231
Cancer Discov. 2014 Mar;4(3):362-75
pubmed: 24346116
Cell Death Differ. 2017 May;24(5):878-888
pubmed: 28362427
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
pubmed: 16166262
Nature. 2005 Jun 2;435(7042):677-81
pubmed: 15902208
Nat Med. 2015 Feb;21(2):178-84
pubmed: 25599133
N Engl J Med. 2016 Jan 28;374(4):311-22
pubmed: 26639348
N Engl J Med. 2018 Mar 22;378(12):1107-1120
pubmed: 29562156
Blood. 2017 Jun 22;129(25):3362-3370
pubmed: 28473407
Nat Med. 2013 Feb;19(2):202-8
pubmed: 23291630
Oncotarget. 2018 Dec 28;9(102):37777-37789
pubmed: 30701031
Front Oncol. 2018 Oct 22;8:458
pubmed: 30406027
Blood Adv. 2019 Dec 23;3(24):4326-4335
pubmed: 31869416
Blood. 2016 Jun 23;127(25):3215-24
pubmed: 27069256
Cell Death Differ. 2018 Jan;25(1):56-64
pubmed: 29077093
Cancer Discov. 2018 Dec;8(12):1566-1581
pubmed: 30185627
Lancet Oncol. 2010 Dec;11(12):1149-59
pubmed: 21094089
Lancet Oncol. 2018 Feb;19(2):216-228
pubmed: 29339097
Biochim Biophys Acta. 2016 Apr;1863(4):562-71
pubmed: 26704388
Nat Commun. 2019 Jun 3;10(1):2385
pubmed: 31160589
Hematol Transfus Cell Ther. 2019 Apr - Jun;41(2):169-177
pubmed: 31084767
Leukemia. 2014 Jul;28(7):1557-60
pubmed: 24531733
Nat Rev Cancer. 2016 Feb;16(2):99-109
pubmed: 26822577
Clin Pharmacol Ther. 2017 Jan;101(1):89-98
pubmed: 27806433
Haematologica. 2018 Sep;103(9):1511-1517
pubmed: 29880613
Cell Death Differ. 2018 Jan;25(1):65-80
pubmed: 29149100
Haematologica. 2019 Sep;104(9):e434-e437
pubmed: 31004028
Blood. 2019 Jul 11;134(2):97-98
pubmed: 31296538
Chronic Dis Transl Med. 2018 Mar 12;4(1):29-44
pubmed: 29756121
Nat Commun. 2018 Aug 29;9(1):3513
pubmed: 30158527
Leuk Lymphoma. 2009 Apr;50(4):559-65
pubmed: 19373653
Leuk Lymphoma. 2014 Sep;55(9):1980-92
pubmed: 24295132
Eur J Haematol. 2019 May;102(5):437-441
pubmed: 30725494
Blood. 2018 Sep 6;132(10):1007-1012
pubmed: 30037885
Front Oncol. 2019 Jan 07;8:645
pubmed: 30666297
Haematologica. 2015 Aug;100(8):e302-6
pubmed: 25957396
Blood. 2020 Mar 5;135(10):709-711
pubmed: 32135019
J Clin Oncol. 2017 Mar 10;35(8):826-833
pubmed: 28095146
Cancer Res. 2018 Jun 1;78(11):3075-3086
pubmed: 29559471
Curr Hematol Malig Rep. 2017 Feb;12(1):11-19
pubmed: 28116634
Blood. 2020 Mar 5;135(10):773-777
pubmed: 31951646
Cell Death Dis. 2019 May 29;10(6):421
pubmed: 31142733
Blood. 1997 Jan 1;89(1):243-55
pubmed: 8978298
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
Cancer Cell. 2006 May;9(5):351-65
pubmed: 16697956
Biomark Res. 2021 May 1;9(1):30
pubmed: 33933163
EMBO J. 2021 Mar 1;40(5):e106700
pubmed: 33439509
Oncotarget. 2017 Mar 7;8(10):16220-16232
pubmed: 27092880
Cancer Cell. 2019 Oct 14;36(4):369-384.e13
pubmed: 31543463
Cell Death Dis. 2017 Jan 12;8(1):e2552
pubmed: 28079887
Oncotarget. 2015 Jul 10;6(19):16912-25
pubmed: 26219338
Cancer Discov. 2019 Mar;9(3):342-353
pubmed: 30514704
Front Pharmacol. 2019 Jun 21;10:697
pubmed: 31293422
Br J Cancer. 2016 Mar 15;114(6):638-41
pubmed: 26954718
Clin Cancer Res. 2015 Nov 15;21(22):5021-9
pubmed: 26567361
BMC Cancer. 2017 Jun 2;17(1):399
pubmed: 28578655
Haematologica. 2016 Mar;101(3):263-5
pubmed: 26928246
Scand J Clin Lab Invest Suppl. 2016;245:S22-5
pubmed: 27433788
Leukemia. 2017 Feb;31(2):272-281
pubmed: 27721426
J Clin Oncol. 2007 Mar 20;25(9):1114-20
pubmed: 17296974
Blood. 2019 Jul 11;134(2):111-122
pubmed: 31023700
Science. 1984 Nov 30;226(4678):1097-9
pubmed: 6093263
Leukemia. 2019 Apr;33(4):905-917
pubmed: 30214012
Expert Rev Hematol. 2015 Jun;8(3):283-97
pubmed: 25912824
J Clin Oncol. 2009 Nov 1;27(31):5208-12
pubmed: 19738118
Am J Hematol. 2018 May 17;:
pubmed: 29770480
Blood. 2016 Aug 18;128(7):934-47
pubmed: 27297795
Blood. 2020 Mar 12;135(11):791-803
pubmed: 31932844
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
Biomed Res Int. 2014;2014:435983
pubmed: 24967369
Blood. 2018 Apr 12;131(15):1704-1711
pubmed: 29305552
Eur J Haematol. 2020 Nov;105(5):588-596
pubmed: 32659848
Br J Pharmacol. 2016 Feb;173(3):471-83
pubmed: 26493374
Haematologica. 1995 Mar-Apr;80(2):98-102
pubmed: 7628759
Blood. 2012 Oct 25;120(17):3501-9
pubmed: 22955911